Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hydrix Limited ( (AU:HYD) ) has provided an update.
Hydrix has secured an initial A$2.5 million contract with SynCardia Systems, a subsidiary of Picard Medical, to commence development of the next-generation fully implantable Total Artificial Heart, known as the Emperor. The multi-stage, multiyear program will see Hydrix design the controller and key subsystems using advanced electronics, software, mechanical and safety-critical engineering, reinforcing its credentials in mechanical circulatory support systems and positioning the company as a preferred global partner for complex cardiovascular device development, while SynCardia retains overall system architecture, regulatory and clinical leadership for the platform.
The most recent analyst rating on (AU:HYD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Hydrix Limited stock, see the AU:HYD Stock Forecast page.
More about Hydrix Limited
Hydrix Limited is an ASX-listed engineering and product development company that provides highly specialised design and development services for complex, safety-critical medical devices, with a growing focus on cardiovascular technologies. Through its Hydrix Services subsidiary, the company partners with international medical technology leaders to deliver long-term, high-value development programs in highly regulated medical device markets.
Average Trading Volume: 360,818
Technical Sentiment Signal: Sell
Current Market Cap: A$3.27M
See more insights into HYD stock on TipRanks’ Stock Analysis page.